HUP9800832A2 - Transzdermális formulált alak - Google Patents

Transzdermális formulált alak

Info

Publication number
HUP9800832A2
HUP9800832A2 HU9800832A HUP9800832A HUP9800832A2 HU P9800832 A2 HUP9800832 A2 HU P9800832A2 HU 9800832 A HU9800832 A HU 9800832A HU P9800832 A HUP9800832 A HU P9800832A HU P9800832 A2 HUP9800832 A2 HU P9800832A2
Authority
HU
Hungary
Prior art keywords
weight
parts
transdermal formulation
xanųmeline
transdermal
Prior art date
Application number
HU9800832A
Other languages
English (en)
Inventor
Franklin P. Bymaster
Michael Horstmann
Harlan E. Shannon
Lisa Ann Shipley
Kirti H. Valia
Original Assignee
Eli Lilly And Co.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Co. filed Critical Eli Lilly And Co.
Publication of HUP9800832A2 publication Critical patent/HUP9800832A2/hu
Publication of HUP9800832A3 publication Critical patent/HUP9800832A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A találmány tárgya transzdermális Xanőmeline tapasz főrműlált alak,amely hatásős mennyiségű xanőmelinetartalmú, ezen túlmenően körülbelül0,1-10 tömegrész azőnt, körülbelül 30-69,8 tömegrész etanőlt,körülbelül 29-50 tömegrész vizet, körülbelül 0-30 tömegrész prőpilén-glikőlt és körülbelül 1-5 tömegrész gélképző szert tartalmaz. Atalálmány szerinti főrműlált alak gyógyszerészetben alkalmazható. ŕ
HU9800832A 1995-01-30 1996-01-16 Transdermal formulation HUP9800832A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38047895A 1995-01-30 1995-01-30

Publications (2)

Publication Number Publication Date
HUP9800832A2 true HUP9800832A2 (hu) 1999-01-28
HUP9800832A3 HUP9800832A3 (en) 2000-07-28

Family

ID=23501315

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9800832A HUP9800832A3 (en) 1995-01-30 1996-01-16 Transdermal formulation

Country Status (23)

Country Link
US (1) US5980933A (hu)
EP (1) EP0723781A3 (hu)
JP (1) JPH10513181A (hu)
KR (1) KR19980701730A (hu)
AR (1) AR001790A1 (hu)
AU (1) AU709379B2 (hu)
BR (1) BR9600216A (hu)
CA (1) CA2210711A1 (hu)
CO (1) CO4700420A1 (hu)
CZ (1) CZ240297A3 (hu)
EA (1) EA001083B1 (hu)
HU (1) HUP9800832A3 (hu)
IL (1) IL116895A (hu)
NO (1) NO973471L (hu)
NZ (1) NZ301197A (hu)
PE (1) PE17397A1 (hu)
PL (1) PL321686A1 (hu)
RO (1) RO117146B1 (hu)
TR (1) TR199700711T1 (hu)
TW (1) TW304167B (hu)
WO (1) WO1996023463A1 (hu)
YU (1) YU5196A (hu)
ZA (1) ZA96530B (hu)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0821956A1 (en) * 1996-08-01 1998-02-04 Eli Lilly And Company Method for treating disruptive behavior disorders
US6117890A (en) * 1996-08-01 2000-09-12 Eli Lilly And Company Method for treating bipolar disorder
US6090829A (en) * 1996-08-01 2000-07-18 Eli Lilly And Company Method for treating excessive aggression
EP0821954A1 (en) * 1996-08-01 1998-02-04 Eli Lilly And Company Method for treating mental retardation
US6043258A (en) * 1996-08-01 2000-03-28 Eli Lilly And Company Method for treating disruptive behavior disorders with xanomeline
US6034108A (en) * 1997-07-28 2000-03-07 Eli Lilly And Company Method for treating mental retardation
US6193993B1 (en) * 1998-03-03 2001-02-27 Eisai Co., Ltd. Suppository containing an antidementia medicament
US6528529B1 (en) 1998-03-31 2003-03-04 Acadia Pharmaceuticals Inc. Compounds with activity on muscarinic receptors
JP5106715B2 (ja) * 1999-09-24 2012-12-26 アルロン・ジャパン株式会社 Ｌ−アスコルビン酸、ｌ−アスコルビン酸誘導体の皮膚真皮層への放出方法に使用するための組成物
JP3962684B2 (ja) * 2000-11-06 2007-08-22 サムヤン コーポレイション 改善された水分吸収能および接着性を有する経皮投与剤
EP1928437A2 (en) 2005-08-26 2008-06-11 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258357A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
DE102005050431A1 (de) * 2005-10-21 2007-04-26 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System zur Verabreicherung lipophiler und/oder wenig hautpermeabler Wirkstoffe
US20070259859A1 (en) * 2006-05-04 2007-11-08 De Bruin Natasja M W J Muscarinic agonists to treat impulse control disorders
DE102010024105A1 (de) * 2010-06-17 2011-12-22 Grünenthal GmbH Transdermale Verabreichung von Memantin
WO2012094360A2 (en) 2011-01-04 2012-07-12 Gordon Chiu Biotherapeutics for the treatment of infectious diseases
EP3265067A4 (en) 2015-03-06 2018-09-12 Chase Pharmaceuticals Corporation Oxybutynin-xanomeline transdermal therapeutic system combinations
CA2996717A1 (en) 2015-09-11 2017-03-16 Chase Pharmaceuticals Corporation Muscarinic combination and its use for combating hypocholinergic disorders of the central nervous system

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4316893A (en) * 1975-06-19 1982-02-23 Nelson Research & Development Co. Vehicle composition containing 1-substituted azacycloalkan-2-ones
US5344656A (en) * 1986-09-12 1994-09-06 Alza Corporation Subsaturated transdermal therapeutic system having improved release characteristics
US4908027A (en) * 1986-09-12 1990-03-13 Alza Corporation Subsaturated transdermal therapeutic system having improved release characteristics
MY102980A (en) * 1986-10-31 1993-03-31 Pfizer Transdermal flux enhancing compositions
ATE76584T1 (de) * 1987-08-28 1992-06-15 Lilly Co Eli Die permeation verbessernde zusammensetzung.
IT1233860B (it) * 1988-02-08 1992-04-21 Isf Spa Derivati del peridroazacicloalca (1,2-a) imidazolo ad attivita' nootropa
DE3843239C1 (hu) * 1988-12-22 1990-02-22 Lohmann Therapie Syst Lts
US5043345A (en) * 1989-02-22 1991-08-27 Novo Nordisk A/S Piperidine compounds and their preparation and use
IE82916B1 (en) * 1990-11-02 2003-06-11 Elan Corp Plc Formulations and their use in the treatment of neurological diseases
DK198590D0 (da) * 1990-08-21 1990-08-21 Novo Nordisk As Heterocykliske forbindelser, deres fremstilling og anvendelse
US5238933A (en) * 1991-10-28 1993-08-24 Sri International Skin permeation enhancer compositions

Also Published As

Publication number Publication date
US5980933A (en) 1999-11-09
EA001083B1 (ru) 2000-10-30
CZ240297A3 (cs) 1998-04-15
IL116895A0 (en) 1996-05-14
KR19980701730A (ko) 1998-06-25
RO117146B1 (ro) 2001-11-30
EP0723781A3 (en) 1996-08-07
AU709379B2 (en) 1999-08-26
AR001790A1 (es) 1997-12-10
EA199700151A1 (ru) 1997-12-30
CO4700420A1 (es) 1998-12-29
JPH10513181A (ja) 1998-12-15
IL116895A (en) 2000-08-31
PE17397A1 (es) 1997-05-21
WO1996023463A1 (en) 1996-08-08
NZ301197A (en) 1999-09-29
PL321686A1 (en) 1997-12-22
NO973471L (no) 1997-09-19
NO973471D0 (no) 1997-07-28
BR9600216A (pt) 1998-01-06
YU5196A (sh) 1998-08-14
AU4656596A (en) 1996-08-21
ZA96530B (en) 1997-07-23
TW304167B (hu) 1997-05-01
EP0723781A2 (en) 1996-07-31
HUP9800832A3 (en) 2000-07-28
TR199700711T1 (xx) 1998-01-21
CA2210711A1 (en) 1996-08-08
MX9705723A (es) 1997-11-29

Similar Documents

Publication Publication Date Title
HUP9800832A2 (hu) Transzdermális formulált alak
CA2259297A1 (en) Parenteral paclitaxel in a stable non-toxic formulation
CA2268140A1 (en) Pharmaceutical gel preparation applicable to mucosal surfaces and body tissues
ES2158911T3 (es) Formulaciones en aerosol sin clorofluorocarbonos.
DK0711140T3 (da) Antimykotisk opløsning til negle
ES2172654T3 (es) Uso de nsaid para el tratamiento de carcinomas de celulas escamosas de la cavidad oral u orofaringe.
DE69803940D1 (de) Ophthalmische zusammensetzungen mit verlängerte freisetzung enthaltend im wasser lösliche arzneistoffe
ES2051345T3 (es) Antisudorante y desodorante.
DK0436217T3 (da) Antiinflammatorisk analgetisk plaster
ES2183223T3 (es) Composicion para uso veterinario intramamaria que no contiene agentes antiinflamatorios.
FR2779648B1 (fr) Composition cosmetique ou pharmaceutique se presentant sous forme de solide et pouvant etre deformable
GR3030528T3 (en) Viscoelastic compositions of fluorinated organic compounds
HUP9602498A2 (hu) Antimikrobiális hatású gyógyászati készítmények
ES2181763T3 (es) Formulaciones a base de fenbendazol.
IE44909L (en) Dental plaque disclosing agent
MY124480A (en) Use of glyceryl triacetate for treating onychomycoses
KR910009279A (ko) 세포 보호제 조성물
ID23449A (id) Komposisi kimia
JPS56161323A (en) Anti-inflammatory and pain-killing gel
JPS5750914A (en) Betamethasone external pharmaceutical
PT850043E (pt) Composicao para normalizar a pele contendo goma de silicone mistura de polioxietilenos e composto de glicerol
CA2246795A1 (en) Insect repellent
HUP9901862A2 (hu) Eljárás fokozott ellenállású és stabilitású ón-fluorid foggél előállítására
ES8702367A1 (es) Un metodo para la produccion de una preparacion gelatinosa antimicotica.
ES2131482A1 (es) Formulacion acuosa de bambuterol.